Examining immunity markers in ICU patients with ventilator-associated pneumonia
Monitoring of Immunity Markers in Intensive Care Patients and Link with Recurrence and Relapse of Ventilator-associated Pneumonia
This study is trying to see if measuring certain immune markers in ICU patients with ventilator-associated pneumonia can help improve their treatment and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Intercommunal Aix-Pertuis Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Aix-en-Provence) |
| Trial ID | NCT06607055 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the relationship between the recurrence of ventilator-associated pneumonia (VAP) and postaggressive immunoparalysis in patients admitted to the Intensive Care Unit (ICU). It will monitor HLA-DR levels in blood samples taken from participants at the time of inclusion and weekly thereafter. The study seeks to evaluate associations between immunoplegia, severity of initial shock, viral reactivation, and VAP occurrence, with the goal of improving antibiotic therapy and patient outcomes. By identifying patients at risk for infections, the study may inform future immunomodulatory therapies.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old who are admitted to the ICU, under mechanical ventilation, and diagnosed with infectious pneumonia.
Not a fit: Patients under 18 years old, those with severe neutropenia, or those on immunosuppressive treatments are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of ventilator-associated pneumonia and reduced mortality in ICU patients.
How similar studies have performed: While the approach of monitoring immunity markers in ICU patients is being explored, this specific correlation between HLA-DR levels and VAP recurrence is less established, indicating a novel area of investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over 18 years old * Patient admitted in the Intensive Care Unit of the CHIAP * Patient under mechanical ventilation * Patient with infectious pneumonia * Informed Consent Form (ICF) obtained from the patient or emergency ICF obtained from close relatives * Patient beneficiary of French social security, whatever the regime Exclusion Criteria: * Patient under 18 years old * Patient with severe neutropenia (neutrophils \< 0.5 G/L) * Patient under immunosuppressive treatment * Use of corticosteroids (intravenous or oral) prior to ICU admission * Use of therapeutic antibodies * Onco-hematological disease (e.g. lymphoma, leukemia...) under treatment or treated in the 5 years prior to inclusion * End of chemotherapy 6 months prior to inclusion * Patients with innate or acquired immune deficiency (e.g., severe combined immunodeficiency, HIV or AIDS, at any stage) * Patients with a decision to limit or discontinue active therapies, at the time of inclusion * Patients with an estimated ICU stay of less than 48 hours * Participation in an interventional study * Patient deprived of their liberty * Patient under tutorship or curatorship * Pregnant or breastfeeding woman
Where this trial is running
Aix-en-Provence
- Centre Hospitalier Intercommunal Aix-Pertuis — Aix-en-Provence, France (Recruiting)
Study contacts
- Principal investigator: Laurent LEFEBVRE, MD — Centre Hospitalier Intercommunal Aix-Pertuis
- Study coordinator: Laurent LEFEBVRE, MD
- Email: llefebvre@ch-aix.fr
- Phone: 0442335650
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.